There are currently 446 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
08/12/2025
Locations: University of Kansas Medical Center (Neurology), Kansas City, Kansas
Conditions: Parkinson Disease
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150
Recruiting
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/12/2025
Locations: University of Kansas Medical Center-Kansas City, Kansas City, Kansas
Conditions: Non-cystic Fibrosis Bronchiectasis
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: University of Kansas Medical Center- Site Number : 8400084, Kansas City, Kansas
Conditions: Multiple Sclerosis
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919
Recruiting
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Gender:
ALL
Ages:
Between 1 year and 3 years
Trial Updated:
08/11/2025
Locations: The University of Kansas Health System - Main Campus, Medical Pavilion, Kansas City, Kansas
Conditions: Allergy, Peanut Allergy
Register for Updates
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941
Recruiting
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Sjögren's Syndrome
Register for Updates
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
NCT05476497
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/11/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Peanut Allergy
Register for Updates
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085
Recruiting
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Kansas City VA Medical Center, Kansas City, Kansas
Conditions: Lymphoma
Register for Updates
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Register for Updates
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801
Recruiting
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397
Recruiting
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2025
Locations: University of Kansas School of Medicine, Kansas City, Kansas
Conditions: Fabry Disesase
Register for Updates